SCHEMBL2471874

SCHEMBL2471874

CCc1c(C(=O)c2cc(C)cc(C)c2)n(CC2=CCCC2)c(=O)[nH]c1=O

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
TDP1 Q9NUW8 3/20 0.36
ALDH1A1 P00352 10/20 0.34
HSD17B10 Q99714 3/20 0.34
USP2 O75604 2/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 6/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
KDM4E B2RXH2 2/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 2/20 0.32
CASP1 P29466 2/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7068567 0.90 ALDH1A1 (0.42) MEN1KMT2ATDP1ALDH1A1HSD17B10
SCHEMBL675376 0.85 MEN1 (0.35) MEN1KMT2ATDP1ALDH1A1HSD17B10
SCHEMBL6089500 0.82 TPH1 (0.38) MEN1KMT2ATDP1ALDH1A1LMNA
SCHEMBL12752168 0.80 KMT2A (0.40) MEN1KMT2ATDP1ALDH1A1HSD17B10
SCHEMBL2465302 0.80 MEN1 (0.32) MEN1KMT2ATDP1
SCHEMBL6087483 0.79 MEN1 (0.43) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL2471690 0.79 ALDH1A1 (0.32) MEN1KMT2ATDP1ALDH1A1HSD17B10
SCHEMBL6087754 0.78 KMT2A (0.39) MEN1KMT2ATDP1ALDH1A1HSD17B10
SCHEMBL6086074 0.77 MEN1 (0.35) MEN1KMT2ATDP1ALDH1A1LMNA
SCHEMBL6089230 0.77 TYMS (0.38) MEN1KMT2ATDP1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986651-B1 USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C SAMJIN PHARM CO LTD (KR) 2011-10-05 EP claimed
US-7851479-B2 Use of pyrimidinedione derivative for preventing or treating hepatitis C SAMJIN PHARM. CO., LTD. (KR) 2010-12-14 US claimed
US-20090023764-A1 Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C SAMJIN PHARM. CO., LTD. (KR) 2009-01-22 US claimed
EP-1986651-A1 USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C Samjin Pharmaceutical Co., Ltd. (KR) 2008-11-05 EP claimed
WO-2007091857-A1 USE OF A PYRIMIDINEDIONE DERIVATIVE FOR PREVENTING OR TREATING HEPATITIS C SAMJIN PHARM. CO., LTD. (KR) 2007-08-16 WO claimed
US-7851479-B2 Use of pyrimidinedione derivative for preventing or treating hepatitis C SAMJIN PHARM. CO., LTD. (KR) 2010-12-14 US disclosed
US-7851479-B2 Use of pyrimidinedione derivative for preventing or treating hepatitis C SAMJIN PHARM. CO., LTD. (KR) 2010-12-14 US disclosed
US-20090023764-A1 Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C SAMJIN PHARM. CO., LTD. (KR) 2009-01-22 US disclosed
US-20090023764-A1 Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C SAMJIN PHARM. CO., LTD. (KR) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023764-A1 Use of Pyrimidinedione Derivative for Preventing or Treating Hepatitis C DPYD, UMPS, TYMP MEN1 4693/4885KMT2A 4444/4885TDP1 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.